Publications
54
Citations
137
Est. group size
~5
Recurring co-author estimate
Active years
15
Publishing since 2012
James Lin Chen's research focuses on sarcoma (a type of cancer that develops in bone or soft tissue) and other cancers, studying how biomarkers—such as blood-based tumor DNA, immune cell ratios, and gene expression—can predict how patients respond to treatments like immunotherapy and chemotherapy. He also works on improving how genomic test results and patient-reported health data are integrated into electronic health records to make cancer care more efficient and data-driven.
Publication output rose to a peak around 2022 and has gradually declined in recent years, though the researcher continues to publish steadily.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Patient-reported global health to predict negative health outcomes in patients with advanced sarcoma.
Journal of Clinical Oncology · 2026
- Longitudinal assessment of circulating tumor DNA as a disease monitoring biomarker in soft tissue sarcoma.
Journal of Clinical Oncology · 2026
- Neutrophil-to-lymphocyte ratio as a clinical biomarker for immune checkpoint inhibitor response in advanced sarcoma.
Journal of Clinical Oncology · 2025
- Implementation of a pre-treatment readiness tool for soft tissue and bone sarcoma.
Journal of Clinical Oncology · 2025
- Real-world evaluation of the reduction in complexity of ordering DNA sequencing tests through the adoption of Fast Healthcare Interoperability Resources (FHIR) standards.
Journal of Clinical Oncology · 2025
- Changes in non-small cell lung cancer (NSCLC) next-generation sequencing (NGS) rates after electronic health record (EHR) integration using large-scale, multi-institutional, real-world data.
Journal of Clinical Oncology · 2024
- Quantifying clinical actionability of updated tumor profiling reports through electronic health record (EHR)-enabled, on-demand ordering and resulting.
Journal of Clinical Oncology · 2024
- Patient-reported global health to predict adverse health outcomes in an expanded cohort of patients with advanced sarcoma.
Journal of Clinical Oncology · 2024
- Exchanging genomics reports between pathology labs and medical centers using the Minimal Clinical Oncology Data Element (mCODE) FHIR implementation guide.
Journal of Clinical Oncology · 2023
- Time savings from integrating discrete, genomic data into the electronic health record using the Epic Aura Network.
Journal of Clinical Oncology · 2023
- DCK expression by RNAseq as a potential biomarker of gemcitabine response in sarcoma.
Journal of Clinical Oncology · 2023
- Chondrosarcoma: The OSU experience.
Journal of Clinical Oncology · 2023
- Correlative results from NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.
Journal of Clinical Oncology · 2022
- <i>nab</i>-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program.
Journal of Clinical Oncology · 2022
- A phase 2 study of anti-PD-L1 antibody (atezolizumab) in grade 2 and 3 chondrosarcoma.
Journal of Clinical Oncology · 2022
- Journal of Clinical Oncology×50
- Nathan D. Seligson
Medicine · The Ohio State University
- Ryan D. Roberts
Medicine · The Ohio State University
- Marcus R. Breese
Medicine · Indiana University
- Pankita H. Pandya
Medicine · Indiana University
- Scott Lenobel
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile